On March 11, 2026 Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), ("Amplia" or the "Company"), focused on the development of drugs for pancreatic cancer, reported that CEO and Managing Director Dr. Chris Burns, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th (US time)/March 13th (AU time), 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
DATE: March 12th (US)/ March 13th (AU)
TIME: 3:30 – 4:00 pm US EDT; 6:30 – 7:00 am AEDT
REGISTER HERE
Available for 1×1 meetings: March 12-17. Schedule 1×1 Meetings here.
The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
Updated ORR of 42% and mPFS of 7.7 mo in ACCENT trial of narmafotinib in metastatic pancreatic cancer
Opening of US sites in second pancreatic cancer trial
Alignment with FDA on structure of planned registrational Phase 2b/3 trial
Compelling preclinical data highlighting clinical potential of narmafotinib combination with kRAS inhibitors in pancreatic and other cancers
(Press release, Amplia Therapeutics, MAR 11, 2026, View Source [SID1234663464])